Wall Street Zen upgraded shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.
A number of other brokerages have also recently weighed in on UNCY. Guggenheim restated a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday. Zacks Research downgraded shares of Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Weiss Ratings upgraded shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. HC Wainwright decreased their price target on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. Finally, Benchmark cut their price objective on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a research report on Wednesday, July 1st. Five equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $18.25.
Check Out Our Latest Analysis on Unicycive Therapeutics
Unicycive Therapeutics Price Performance
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.41. Equities research analysts anticipate that Unicycive Therapeutics will post -1.17 earnings per share for the current year.
Institutional Trading of Unicycive Therapeutics
Institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC acquired a new position in shares of Unicycive Therapeutics during the 2nd quarter worth about $55,000. JPMorgan Chase & Co. raised its position in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Unicycive Therapeutics during the 1st quarter worth about $161,000. Citadel Advisors LLC purchased a new stake in Unicycive Therapeutics during the third quarter worth approximately $182,000. Finally, Bank of America Corp DE lifted its stake in Unicycive Therapeutics by 19,327.6% during the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after purchasing an additional 29,378 shares during the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Featured Stories
- Five stocks we like better than Unicycive Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
